featured
Impact of Age and Performance Status on Outcomes With First-Line Pembrolizumab for Advanced Urothelial Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles: